Collateral for a security interest recorded Dec 19, 2012 (Biopharma Secured Debt Fund II Holdings Cayman LP).
Term ends Feb 9, 2030 · Medium confidence
20-year base term ends Apr 29, 2030
Why Medium: The disclaimer's references carry disclaimers of their own not yet read (US 8,293,727, US 8,293,728, US 8,314,086), so the cap could be lower.
Filed Sep 13, 2012 as application 13/614,129 · Granted May 21, 2013
Base term, 20 years from filing · capped by a resolved terminal disclaimer
Today
2010
2030
Clock starts
Apr 29, 2010
Apr 29, 2010
Term ends
Feb 9, 2030
Feb 9, 2030
Granted
May 21, 2013
May 21, 2013
base term
after the term ends
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 8,293,727, US 8,293,728, US 8,314,086.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
29
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. All three maintenance fees are recorded paid; no more fees are due. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Apr 29, 2010, when application 12/769,885, the earliest non-provisional in its chain, was filed (this one was filed Sep 13, 2012) | Apr 29, 2030 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,293,727, US 8,293,728, US 8,314,086) | capped to Feb 9, 2030 | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Feb 9, 2030 | Medium confidence |
This family
| US 8,298,554 | In force Oct 2030 | Oct 2030 |
| US 8,445,003 | In force Feb 2030 | Feb 2030 |
| US 8,454,994 | In force Apr 2030 | Apr 2030 |
| US 8,501,225 | In force Feb 2030 | Feb 2030 |
| US 8,445,013 | this patent Feb 2030 | Feb 2030 |
| US 8,613,945 | Lapsed on the fee record Dec 2025 | Dec 2025 |
| US 8,663,662 | Lapsed on the fee record Mar 2026 | Mar 2026 |
| US 8,623,406 | Lapsed on the fee record Jan 2026 | Jan 2026 |
8 of 29 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Oct 30, 2012 Reel 29212, frame 981 | Manku, Mehar; Osterloh, Ian; Wicker, Pierre; Braeckman, Rene; Soni, Paresh | Amarin Pharmaceuticals Ireland Limited | Assignment of Assignor's Interest |
| Dec 19, 2012 Reel 29499, frame 87 | Amarin Pharmaceuticals Ireland Limited | Biopharma Secured Debt Fund II Holdings Cayman LP | Security Agreement |
| Dec 20, 2017 Reel 44956, frame 395 | Biopharma Secured Debt Fund II Holdings Cayman LP | Cppib Credit Europe S.À R.L. | Patent Security Assignment and Assumption Agreement |
| Dec 21, 2017 Reel 44938, frame 257 | Amarin Pharmaceuticals Ireland Limited | Cppib Credit Europe S.À R.L. | Security Interest |
| Nov 19, 2020 Reel 54484, frame 552 | Cppib Credit Europe S.À R.L. | Amarin Pharmaceuticals Ireland Limited | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Feb 2030
Term ends Feb 9, 2030. No further fees fall due before then
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 8,293,727, US 8,293,728, US 8,314,086.
Citations
112
later US patents cite this one
That is top 5% of utility patents granted in 2013 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.